^
    Back
    Association details:
    Biomarker:MRC1 expression
    Cancer:Small Cell Lung Cancer
    Drug:nibrozetone (RRx-001) (CD47 inhibitor, MYC inhibitor, NLRP3 inhibitor, SIRPA antagonist, NRF2 activator)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Expert Opin Investig Drugs
    Title:

    Results from a biomarker study to accompany a phase II trial of RRx-001 with reintroduced platinum-based chemotherapy in relapsed small cell carcinoma

    Published date:
    01/11/2021
    Excerpt:
    CD206 expression on HLA-DRlow/- monocytes was associated with response to chemotherapy and overall survival….During treatment with RRx-001, reduced expression of the protumorigenic M2 marker CD206 on peripheral monocytes positively correlated with increased response and survival.
    DOI:
    10.1080/13543784.2021.1863947